Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9. https://doi.org/10.1097/01.sla.0000217629.94941.cf.

Article  PubMed  PubMed Central  Google Scholar 

Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810. https://doi.org/10.1186/1471-2407-14-810.

Article  PubMed  Google Scholar 

Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. https://doi.org/10.1200/JCO.2007.11.0833.

Article  PubMed  Google Scholar 

House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52, 52-5. https://doi.org/10.1016/j.jamcollsurg.2009.12.040.

Article  PubMed  Google Scholar 

Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73(9):727–31. https://doi.org/10.1002/bjs.1800730917.

CAS  Article  PubMed  Google Scholar 

Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):91–103. https://doi.org/10.1111/j.1477-2574.2012.00557.x.

Article  PubMed Central  Google Scholar 

Nagano Y, Nojiri K, Matsuo K, Tanaka K, Togo S, Ike H, et al. The impact of advanced age on hepatic resection of colorectal liver metastases. J Am Coll Surg. 2005;201(4):511–6. https://doi.org/10.1016/j.jamcollsurg.2005.05.010.

Article  PubMed  Google Scholar 

Langella S, Russolillo N, Forchino F, Lo Tesoriere R, D'Eletto M, Ferrero A. Impact of obesity on postoperative outcome of hepatic resection for colorectal metastases. Surgery. 2015;158(6):1521–9. https://doi.org/10.1016/j.surg.2015.07.024.

Article  PubMed  Google Scholar 

Elias DM, Ouellet JF. Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin N Am. 2003;12(1):221–9. https://doi.org/10.1016/s1055-3207(02)00080-7.

Article  PubMed  Google Scholar 

Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51. https://doi.org/10.1200/JCO.2008.17.5299.

Article  PubMed  Google Scholar 

Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8. https://doi.org/10.1016/j.suronc.2018.05.012.

Article  PubMed  Google Scholar 

Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127(5):512–9. https://doi.org/10.1067/msy.2000.105294.

CAS  Article  PubMed  Google Scholar 

Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94(11):1386–94. https://doi.org/10.1002/bjs.5836.

CAS  Article  PubMed  Google Scholar 

Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014;12:391. https://doi.org/10.1186/1477-7819-12-391.

Article  PubMed  PubMed Central  Google Scholar 

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. https://doi.org/10.1016/S1470-2045(13)70447-9.

CAS  Article  PubMed  Google Scholar 

Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford). 2016;18(6):485–93. https://doi.org/10.1016/j.hpb.2016.03.001.

Article  Google Scholar 

Araujo RL, Gonen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(9):3070–8. https://doi.org/10.1245/s10434-014-4354-6.

Article  PubMed  Google Scholar 

Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41(9):1197–203. https://doi.org/10.1016/j.ejso.2015.05.020.

Article  PubMed  Google Scholar 

Goere D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91. https://doi.org/10.1097/SLA.0b013e3181d35983.

Article  PubMed  Google Scholar 

Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71. https://doi.org/10.1200/JCO.2008.20.1301.

Article  PubMed  PubMed Central  Google Scholar 

Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–20; discussion 20-2. https://doi.org/10.1097/00000658-199610000-00009.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6. https://doi.org/10.1200/JCO.2006.09.0928.

CAS  Article  PubMed  Google Scholar 

Maeda Y, Shinohara T, Nagatsu A, Futakawa N, Hamada T. Long-term outcomes of conversion hepatectomy for initially unresectable colorectal liver metastases. Ann Surg Oncol. 2016;23(Suppl 2):S242–8. https://doi.org/10.1245/s10434-015-4460-0.

Article  PubMed  Google Scholar 

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72. https://doi.org/10.1200/JCO.2005.05.3074.

CAS  Article  PubMed  Google Scholar 

Zhao J, van Mierlo KMC, Gomez-Ramirez J, Kim H, Pilgrim CHC, Pessaux P, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104(8):990–1002. https://doi.org/10.1002/bjs.10572.

CAS  Article  PubMed  Google Scholar 

Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009;14(11):1095–105. https://doi.org/10.1634/theoncologist.2009-0152.

Article  PubMed  Google Scholar 

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83. https://doi.org/10.1200/JCO.2008.20.5278.

Article  PubMed  PubMed Central  Google Scholar 

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. https://doi.org/10.1056/NEJMoa032691.

CAS  Article  PubMed  Google Scholar 

Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108(8):1566–70. https://doi.org/10.1038/bjc.2013.140.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, et al. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol. 2019;24(5):516–25. https://doi.org/10.1007/s10147-018-01393-8.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Tang W, Ren L, Liu T, Ye Q, Wei Y, He G, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME Randomized Controlled Trial. J Clin Oncol. 2020;38(27):3175–84. https://doi.org/10.1200/JCO.20.00174This trial was designed for patients with RAS mutant disease and found that the addition of bevacizumab increased the resectability of liver metastases and increased survival compared to chemotherapy alone.

CAS  Article  PubMed  Google Scholar 

Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–8. https://doi.org/10.1093/annonc/mdu580This study found that in comparison to doublet chemotherapy with bevacizumab, triplet chemotherapy with bevacizumab had superior resection rates and response rates in patients with initially unresectable liver metastases.

CAS  Article  PubMed  Google Scholar 

Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22(9):2042–8. https://doi.org/10.1093/annonc/mdq714.

CAS  Article  PubMed  Google Scholar 

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. https://doi.org/10.1200/JCO.2012.42.8201.

CAS  Article  PubMed